Search Results for: LYN

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel IL7 interleukin 7
  • Interleukin-7 signaling
  • Interleukin-7 signaling
Novel IL7R interleukin 7 receptor
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
Novel INPP5D inositol polyphosphate-5-phosphatase D
  • Synthesis of PIPs at the plasma membrane
  • Synthesis of IP3 and IP4 in the cytosol
  • Downstream TCR signaling
  • PECAM1 interactions
  • Interleukin receptor SHC signaling
  • Signaling by CSF1 (M-CSF) in myeloid cells
Novel ITPR1 inositol 1,4,5-trisphosphate receptor type 1
  • PLC beta mediated events
  • Effects of PIP2 hydrolysis
  • Elevation of cytosolic Ca2+ levels
  • DAG and IP3 signaling
  • Role of phospholipids in phagocytosis
  • FCERI mediated Ca+2 mobilization
  • Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
  • Ca2+ pathway
  • cGMP effects
  • Regulation of insulin secretion
  • VEGFR2 mediated cell proliferation
  • Ion homeostasis
  • Ion homeostasis
  • CLEC7A (Dectin-1) induces NFAT activation
  • FCGR3A-mediated IL10 synthesis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Caffeine
  • 1D-myo-inositol 1,4,5-trisphosphate
  • Glycerin
  • Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
Novel JAK2 Janus kinase 2
  • Interleukin-6 signaling
  • Interleukin-6 signaling
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • Prolactin receptor signaling
  • Prolactin receptor signaling
  • Signaling by SCF-KIT
  • Signaling by Leptin
  • RMTs methylate histone arginines
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RAF activation
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • IL-6-type cytokine receptor ligand interactions
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Cyclin D associated events in G1
  • Interferon gamma signaling
  • Regulation of IFNG signaling
  • Regulation of IFNG signaling
  • Interleukin-20 family signaling
  • Interleukin-35 Signalling
  • Signaling by Erythropoietin
  • Signaling by Erythropoietin
  • Interleukin-12 signaling
  • Interleukin-12 signaling
  • Interleukin-23 signaling
  • Interleukin-23 signaling
  • Interleukin-27 signaling
  • Interleukin-27 signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Interleukin receptor SHC signaling
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Potential therapeutics for SARS
  • Inactivation of CSF3 (G-CSF) signaling
  • Inactivation of CSF3 (G-CSF) signaling
  • IFNG signaling activates MAPKs
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • Factors involved in megakaryocyte development and platelet production
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • XL019
  • 5-phenyl-1H-indazol-3-amine
  • 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide
  • 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
  • Ruxolitinib
  • Tofacitinib
  • Pacritinib
  • Baricitinib
  • Entrectinib
  • Fostamatinib
  • Fedratinib
  • Abrocitinib
  • Zanubrutinib
  • Pralsetinib
  • Polycythemia vera
Novel KHDRBS1 KH RNA binding domain containing, signal transduction associated 1
  • PTK6 Regulates Proteins Involved in RNA Processing
Novel KIT KIT proto-oncogene, receptor tyrosine kinase
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Regulation of KIT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Dasatinib-resistant KIT mutants
  • Imatinib-resistant KIT mutants
  • KIT mutants bind TKIs
  • Masitinib-resistant KIT mutants
  • Nilotinib-resistant KIT mutants
  • Regorafenib-resistant KIT mutants
  • Signaling by kinase domain mutants of KIT
  • Sunitinib-resistant KIT mutants
  • Signaling by juxtamembrane domain KIT mutants
  • Sorafenib-resistant KIT mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by extracellular domain mutants of KIT
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Alveolar Cells
  • Sorafenib
  • Imatinib
  • Dasatinib
  • Sunitinib
  • Phosphonotyrosine
  • Nilotinib
  • XL820
  • OSI-930
  • Linifanib
  • Pazopanib
  • Midostaurin
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Ancestim
  • Tivozanib
  • Fostamatinib
  • Erdafitinib
  • Amuvatinib
  • Pexidartinib
  • Ripretinib
  • Avapritinib
  • Acute myeloid leukemia (AML)
  • Piebaldism
Novel KLHL41 kelch like family member 41
  • Neddylation
  • Antigen processing: Ubiquitination & Proteasome degradation
Novel LCP2 lymphocyte cytosolic protein 2
  • GPVI-mediated activation cascade
  • Generation of second messenger molecules
  • Generation of second messenger molecules
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
Novel LIME1 Lck interacting transmembrane adaptor 1
Novel MAP4K1 mitogen-activated protein kinase kinase kinase kinase 1
  • Fostamatinib
Novel MAPK3 mitogen-activated protein kinase 3
  • MAPK3 (ERK1) activation
  • RAF-independent MAPK1/3 activation
  • ISG15 antiviral mechanism
  • Signaling by NODAL
  • Spry regulation of FGF signaling
  • Signaling by Activin
  • Frs2-mediated activation
  • ERK/MAPK targets
  • ERK/MAPK targets
  • ERKs are inactivated
  • Regulation of actin dynamics for phagocytic cup formation
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Oncogene Induced Senescence
  • FCERI mediated MAPK activation
  • Regulation of HSF1-mediated heat shock response
  • NCAM signaling for neurite out-growth
  • RSK activation
  • Signal transduction by L1
  • Activation of the AP-1 family of transcription factors
  • Thrombin signalling through proteinase activated receptors (PARs)
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate NADPH Oxidases
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RNA Polymerase I Promoter Opening
  • Signal attenuation
  • Interferon gamma signaling
  • Advanced glycosylation endproduct receptor signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • ESR-mediated signaling
  • RUNX2 regulates osteoblast differentiation
  • Regulation of PTEN gene transcription
  • Regulation of the apoptosome activity
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Suppression of apoptosis
  • Signaling downstream of RAS mutants
  • Signaling by MAP2K mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated phagocytosis
  • Nuclear events stimulated by ALK signaling in cancer
  • IFNG signaling activates MAPKs
  • Negative Regulation of CDH1 Gene Transcription
  • NPAS4 regulates expression of target genes
  • NPAS4 regulates expression of target genes
  • Growth hormone receptor signaling
  • Signaling by LTK in cancer
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Sulindac
  • Acetylsalicylic acid
  • Minocycline
  • Arsenic trioxide
  • Colforsin
  • Purvalanol
  • 5-iodotubercidin
  • Seliciclib
  • Cholecystokinin
  • Ulixertinib
Novel MATK megakaryocyte-associated tyrosine kinase
  • Downregulation of ERBB2 signaling
  • Fostamatinib
Novel MET MET proto-oncogene, receptor tyrosine kinase
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D mediated inhibition of cell attachment and migration
  • RAF/MAP kinase cascade
  • MET Receptor Activation
  • Negative regulation of MET activity
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates RAS signaling
  • MET activates PI3K/AKT signaling
  • MET activates PTPN11
  • MET activates PTK2 signaling
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • MET interacts with TNS proteins
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • MET activates STAT3
  • MECP2 regulates neuronal receptors and channels
  • Drug-mediated inhibition of MET activation
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Sunitinib
  • K-252a
  • SGX-523
  • 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide
  • N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide
  • 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide
  • N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide
  • 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol
  • AMG-208
  • 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE
  • Crizotinib
  • Cabozantinib
  • Capmatinib
  • Tivozanib
  • Fostamatinib
  • Tivantinib
  • Brigatinib
  • Amuvatinib
  • Tepotinib
  • Amivantamab
  • Cholangiocarcinoma
  • Gastric cancer
  • Renal cell carcinoma
Novel MME membrane metalloendopeptidase
  • Metabolism of Angiotensinogen to Angiotensins
  • Physiological factors
  • Neutrophil degranulation
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Candoxatril
  • Omapatrilat
  • N-[3-[(1-Aminoethyl)(Hydroxy)Phosphoryl]-2-(1,1'-Biphenyl-4-Ylmethyl)Propanoyl]Alanine
  • Phosphoramidon
  • N-(3-Phenyl-2-Sulfanylpropanoyl)Phenylalanylalanine
  • [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala
  • Daglutril
  • 2-[(1S)-1-BENZYL-2-SULFANYLETHYL]-1H-IMIDAZO[4,5-C]PYRIDIN-5-IUM
  • Thiorphan
  • Sacubitril
  • Candoxatrilat
Novel MS4A1 membrane spanning 4-domains A1
  • Rituximab
  • Ibritumomab tiuxetan
  • Tositumomab
  • Ofatumumab
  • Obinutuzumab
  • Technetium Tc-99m nofetumomab merpentan
  • Ublituximab
  • Ocrelizumab
  • Mosunetuzumab
  • Odronextamab
Novel MS4A2 membrane spanning 4-domains A2
  • Fc epsilon receptor (FCERI) signaling
  • Fc epsilon receptor (FCERI) signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated NF-kB activation
  • Omalizumab
  • Asthma
Novel MUC1 mucin 1, cell surface associated
  • Defective GALNT3 causes HFTC
  • Defective C1GALT1C1 causes TNPS
  • Defective GALNT12 causes CRCS1
  • Dectin-2 family
  • Interleukin-4 and Interleukin-13 signaling
  • O-linked glycosylation of mucins
  • Termination of O-glycan biosynthesis
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Alveolar Cells
  • TG4010
Novel NDFIP2 Nedd4 family interacting protein 2
Novel NEDD9 neural precursor cell expressed, developmentally down-regulated 9

Page 4 out of 14 pages